The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
Creators: name: El Bairi, Khalid
name: Haynes, Harry R
name: Blackley, Elizabeth
name: Fineberg, Susan
name: Shear, Jeffrey
name: Turner, Sophia
name: De Freitas, Juliana Ribeiro
name: Sur, Daniel
name: Amendola, Luis Claudio
name: Gharib, Masoumeh
name: Kallala, Amine
name: Arun, Indu
name: Azmoudeh-Ardalan, Farid
name: Fujimoto, Luciana
name: Sua, Luz F
name: Liu, Shi-Wei
name: Lien, Huang-Chun
name: Kirtani, Pawan
name: Balancin, Marcelo
name: El Attar, Hicham
name: Guleria, Prerna
name: Yang, Wenxian
name: Shash, Emad
name: Chen, I-Chun
name: Bautista, Veronica
name: Do Prado Moura, Jose Fernando
name: Rapoport, Bernardo L
name: Castaneda, Carlos
name: Spengler, Eunice
name: Acosta-Haab, Gabriela
name: Frahm, Isabel
name: Sanchez, Joselyn
name: Castillo, Miluska
name: Bouchmaa, Najat
name: Md Zin, Reena R
name: Shui, Ruohong
name: Onyuma, Timothy
name: Yang, Wentao
name: Husain, Zaheed
name: Willard-Gallo, Karen
name: Coosemans, An
name: Perez, Edith A
name: Provenzano, Elena
name: Ericsson, Paula Gonzalez
name: Richardet, Eduardo
name: Mehrotra, Ravi
name: Sarancone, Sandra
name: Ehinger, Anna
name: Rimm, David L
name: Bartlett, John MS
name: Viale, Giuseppe
name: Denkert, Carsten
name: Hida, Akira I
name: Sotiriou, Christos
name: Loibl, Sibylle
name: Hewitt, Stephen M
name: Badve, Sunil
name: Symmans, William Fraser
name: Kim, Rim S
name: Pruneri, Giancarlo
name: Goel, Shom
name: Francis, Prudence A
name: Inurrigarro, Gloria
name: Yamaguchi, Rin
name: Garcia-Rivello, Hernan
name: Horlings, Hugo
name: Afqir, Said
name: Salgado, Roberto
name: Adams, Sylvia
name: Kok, Marleen
name: Dieci, Maria Vittoria
name: Michiels, Stefan
name: Demaria, Sandra
name: Loi, Sherene
name: International Immuno-Oncology Biomarker Working Group
Publisher: name: Apollo - University of Cambridge Repository
Year: 2021
Subjects: Review Article
/692/53/2423
/692/4028/67/1347
review-article

description: The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.